Azenta Intrinsic Value – Azenta, Receives “Moderate Buy” Consensus Recommendation with $64.20 Target Price from Brokerages

August 8, 2023

🌥️Trending News

Azenta ($NASDAQ:AZTA), Inc. is a rapidly growing publicly-traded company that specializes in innovative technology solutions. Recently, analysts have given Azenta, Inc. a “Moderate Buy” consensus recommendation, with an average target price of $64.20. This recommendation is based on the coverage of the company by five analysts who are presently covering the company. This “Moderate Buy” recommendation is an indication that the analysts are moderately bullish on the stock, and believe that it has potential for further growth.

They also expect the stock to reach a target price of $64.20, which is an increase from its current market price. Investors should take this recommendation into account when making their own investment decisions.

Stock Price

Although the stock went down slightly, AZENTA is still looking promising from an investment point of view. Analysts have observed that AZENTA’s recent financial performance has been strong and they remain optimistic about the company’s growth prospects. Azenta_Receives_Moderate_Buy_Consensus_Recommendation_with_64.20_Target_Price_from_Brokerages”>Live Quote…

About the Company

  • Azenta_Receives_Moderate_Buy_Consensus_Recommendation_with_64.20_Target_Price_from_Brokerages”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Azenta. More…

    Total Revenues Net Income Net Margin
    597.07 -46.5 -5.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Azenta. More…

    Operations Investing Financing
    -449.48 -228.08 -504.43
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Azenta. More…

    Total Assets Total Liabilities Book Value Per Share
    3.25k 354.59 41.87
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Azenta are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -10.5% 5.8% -3.6%
    FCF Margin ROE ROA
    -83.8% -0.5% -0.4%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Azenta Intrinsic Value

    At GoodWhale, we have conducted an analysis of AZENTA’s fundamentals. Our proprietary Valuation Line has calculated an intrinsic value of AZENTA share at around $74.2. Unfortunately, we have noticed that the current price of AZENTA stock is traded at $47.4, which is 36.2% less than its intrinsic value. This means that it is currently undervalued. As a result, investors may find this opportunity attractive and may decide to invest in AZENTA as a potential long term strategy. Azenta_Receives_Moderate_Buy_Consensus_Recommendation_with_64.20_Target_Price_from_Brokerages”>More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company offers a complete suite of products and services that enable researchers to more effectively understand the function and structure of genomes. Azenta‘s products and services are used by scientists around the world to advance their knowledge of genomics and enable them to make discoveries that improve human health. Azenta is a market leader in genomic solutions, with a strong track record of providing the highest quality products and services to its customers. The company’s products and services are used by scientists around the world to advance their knowledge of genomics and enable them to make discoveries that improve human health. Eurobio Scientific, Straumann Holding AG, and Singular Genomics Systems Inc are all major competitors of Azenta in the genomic solutions market.

    – Eurobio Scientific ($BER:E8TN)

    Eurobio Scientific is a biotechnology company that specializes in the development and commercialization of diagnostic tests and products. The company has a market cap of 198.51M as of 2022 and a Return on Equity of 21.05%. Eurobio Scientific’s products are used in the diagnosis and treatment of diseases, such as cancer, HIV/AIDS, and hepatitis. The company’s products are sold in over 60 countries worldwide.

    – Straumann Holding AG ($LTS:0QMV)

    As of 2022, Straumann Holding AG has a market cap of 18.02B and a Return on Equity of 21.04%. The company is a leading provider of dental implants and other oral health products and services.

    – Singular Genomics Systems Inc ($NASDAQ:OMIC)

    Singular Genomics Systems Inc is a company that focuses on providing genomic solutions. Its market cap as of 2022 is 170.64M, and its ROE is -19.33%. The company’s main products are its sequencing services and its software solutions.


    Azenta, Inc. has received a consensus recommendation of “Moderate Buy” from five brokerage analysts. This indicates that the majority of the analysts surveyed have a positive outlook on the stock. The price target consensus is $64.20, which suggests potential upside for investors who purchase the stock. Investors should do their own research and consult with a financial advisor before making any investment decisions.

    Recent Posts

    Leave a Comment